|
US1286A
(en)
*
|
|
1839-08-13 |
|
Richard else |
|
US2809194A
(en)
*
|
|
1957-10-08 |
|
Thiadiazine type natriuretic agents |
|
US3108097A
(en)
*
|
|
1963-10-22 |
|
Ehnojs |
|
FR1103113A
(fr)
|
1954-04-15 |
1955-10-31 |
|
Triméthylol-alcanes et leur procédé de préparation
|
|
FR1217929A
(fr)
|
1958-03-03 |
1960-05-06 |
Ciba Geigy |
Procédé de préparation du 1,1-dioxyde de la 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine et de ses sels
|
|
NL238796A
(enExample)
*
|
1958-05-07 |
|
|
|
|
DE1302648B
(enExample)
|
1960-09-27 |
|
|
|
|
NL127065C
(enExample)
*
|
1964-04-22 |
|
|
|
|
NL137318C
(enExample)
*
|
1964-06-09 |
|
|
|
|
GB1415295A
(en)
|
1971-10-14 |
1975-11-26 |
Orchimed Sa |
Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof
|
|
FI52570C
(fi)
*
|
1969-04-16 |
1977-10-10 |
Sumitomo Chemical Co |
Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi.
|
|
US3692895A
(en)
*
|
1970-09-08 |
1972-09-19 |
Norman A Nelson |
Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
|
|
DE2230383C3
(de)
*
|
1971-10-01 |
1981-12-03 |
Boehringer Mannheim Gmbh, 6800 Mannheim |
Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
|
|
US4148923A
(en)
*
|
1972-05-31 |
1979-04-10 |
Synthelabo |
1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
|
|
US3948973A
(en)
*
|
1972-08-29 |
1976-04-06 |
Sterling Drug Inc. |
Halocyclopropyl substituted phenoxyalkanoic acids
|
|
US4626549A
(en)
*
|
1974-01-10 |
1986-12-02 |
Eli Lilly And Company |
Treatment of obesity with aryloxyphenylpropylamines
|
|
US4179515A
(en)
*
|
1975-02-12 |
1979-12-18 |
Orchimed S. A. |
Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
|
|
US4235896A
(en)
*
|
1975-02-12 |
1980-11-25 |
Orchimed S.A. |
Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
|
|
JPS5195049A
(en)
*
|
1975-02-12 |
1976-08-20 |
|
* **********so*****no***tsu*****************************************ni*no
|
|
US4075000A
(en)
*
|
1975-05-27 |
1978-02-21 |
Eli Lilly And Company |
Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
|
|
US4576753A
(en)
*
|
1975-10-06 |
1986-03-18 |
Fujisawa Pharmaceutical Co., Ltd. |
Azetidinone compounds and processes for preparation thereof
|
|
US4304718A
(en)
*
|
1975-10-06 |
1981-12-08 |
Fujisawa Pharmaceutical Co., Ltd. |
2-Azetidinone compounds and processes for preparation thereof
|
|
US4472309A
(en)
*
|
1975-10-06 |
1984-09-18 |
Fujisawa Pharmaceutical Co., Ltd. |
2-Azetidinone compounds and processes for preparation thereof
|
|
US4166907A
(en)
*
|
1976-11-01 |
1979-09-04 |
E. R. Squibb & Sons, Inc. |
3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
|
|
US4144232A
(en)
*
|
1976-12-23 |
1979-03-13 |
Eli Lilly And Company |
Substituted azetidin-2-one antibiotics
|
|
FR2403078A1
(fr)
*
|
1977-09-19 |
1979-04-13 |
Lafon Labor |
Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
|
|
IT1157365B
(it)
*
|
1977-10-24 |
1987-02-11 |
Sandoz Ag |
Medicamenti per trattare l'obesita' o ridurre il peso del corpo
|
|
FR2408577A1
(fr)
|
1977-11-14 |
1979-06-08 |
Devinter Sa |
Nouveau procede de synthese d'esters para chlorobenzoyl phenoxy isobutyriques
|
|
NZ191762A
(en)
|
1978-10-19 |
1982-09-14 |
Merck & Co Inc |
Hypocholesteremic composition containing cholesterol synthesis inhibitor and anion exchange resin
|
|
US4250191A
(en)
*
|
1978-11-30 |
1981-02-10 |
Edwards K David |
Preventing renal failure
|
|
US4375475A
(en)
*
|
1979-08-17 |
1983-03-01 |
Merck & Co., Inc. |
Substituted pyranone inhibitors of cholesterol synthesis
|
|
US4260743A
(en)
*
|
1979-12-31 |
1981-04-07 |
Gist-Brocades N.V. |
Preparation of β-lactams and intermediates therefor
|
|
US4444784A
(en)
*
|
1980-08-05 |
1984-04-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
|
ES488665A0
(es)
|
1980-02-15 |
1980-12-16 |
Especialidades Farmaco Terape |
Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
|
|
FR2494112B1
(enExample)
|
1980-11-19 |
1986-01-10 |
Laruelle Claude |
|
|
DE3107100A1
(de)
*
|
1981-02-20 |
1982-09-09 |
Schering Ag, 1000 Berlin Und 4619 Bergkamen |
Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
|
|
US4500456A
(en)
*
|
1981-03-09 |
1985-02-19 |
Eli Lilly And Company |
Preparation of 4-fluoroazetidinones using FClO3
|
|
US4784734A
(en)
*
|
1981-04-10 |
1988-11-15 |
Otsuka Kagaku Yakuhin Kabushiki Kaisha |
Azetidinone derivatives and process for the preparation of the same
|
|
US4602003A
(en)
*
|
1982-05-17 |
1986-07-22 |
Medical Research Foundation Of Oregon |
Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
|
|
US4602005A
(en)
*
|
1982-05-17 |
1986-07-22 |
Medical Research Foundation Of Oregon |
Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
|
|
US4534786A
(en)
*
|
1982-06-23 |
1985-08-13 |
Chevron Research Company |
1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
|
|
US4443372A
(en)
*
|
1982-06-23 |
1984-04-17 |
Chevron Research Company |
1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
|
|
US4595532A
(en)
*
|
1983-02-02 |
1986-06-17 |
University Of Notre Dame Du Lac |
N-(substituted-methyl)-azetidin-2-ones
|
|
CA1256650A
(en)
*
|
1983-03-25 |
1989-06-27 |
Toshinari Tamura |
Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
|
|
DE3484362D1
(de)
*
|
1983-03-28 |
1991-05-08 |
Ciba Geigy Ag |
Verfahren zur herstellung von optisch aktiven azetidinonen.
|
|
US4675399A
(en)
*
|
1983-03-28 |
1987-06-23 |
Notre Dame University |
Cyclization process for β-lactams
|
|
WO1985004876A1
(fr)
*
|
1984-04-24 |
1985-11-07 |
Takeda Chemical Industries, Ltd. |
Derives de 2-azetidinone et leur procede de preparation
|
|
US4576749A
(en)
*
|
1983-10-03 |
1986-03-18 |
E. R. Squibb & Sons, Inc. |
3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
|
|
US5229510A
(en)
*
|
1983-12-01 |
1993-07-20 |
Merck & Co., Inc. |
β-lactams useful in determining the amount of elastase in a clinical sample
|
|
US4680391A
(en)
*
|
1983-12-01 |
1987-07-14 |
Merck & Co., Inc. |
Substituted azetidinones as anti-inflammatory and antidegenerative agents
|
|
US5229381A
(en)
*
|
1983-12-01 |
1993-07-20 |
Merck & Co., Inc. |
Substituted azetidinones as anti-inflammatory and antidegenerative agents
|
|
US4654362A
(en)
*
|
1983-12-05 |
1987-03-31 |
Janssen Pharmaceutica, N.V. |
Derivatives of 2,2'-iminobisethanol
|
|
FR2561916B1
(fr)
*
|
1984-03-30 |
1987-12-11 |
Lafon Labor |
Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
|
|
US4581170A
(en)
*
|
1984-08-03 |
1986-04-08 |
E. R. Squibb & Sons, Inc. |
N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
|
|
US4633017A
(en)
*
|
1984-08-03 |
1986-12-30 |
E. R. Squibb & Sons, Inc. |
N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
|
|
US4576748A
(en)
*
|
1984-09-17 |
1986-03-18 |
Merck & Co., Inc. |
3-Hydroxy-3-aminoethyl β-lactams
|
|
US4647576A
(en)
|
1984-09-24 |
1987-03-03 |
Warner-Lambert Company |
Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
|
|
US4620867A
(en)
*
|
1984-09-28 |
1986-11-04 |
Chevron Research Company |
1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
|
|
AR240698A1
(es)
*
|
1985-01-19 |
1990-09-28 |
Takeda Chemical Industries Ltd |
Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
|
|
US4642903A
(en)
*
|
1985-03-26 |
1987-02-17 |
R. P. Scherer Corporation |
Freeze-dried foam dosage form
|
|
US4680289A
(en)
*
|
1985-06-05 |
1987-07-14 |
Progenics, Inc. |
Treatment of obesity and diabetes using sapogenins
|
|
JPH0679559B2
(ja)
|
1985-06-06 |
1994-10-12 |
三共株式会社 |
光学活性アゼチジノン誘導体の製法
|
|
JPH01501470A
(ja)
|
1986-01-23 |
1989-05-25 |
ジ・アップジョン・カンパニ− |
抗菌性ｎ−アシル−２−アゼチジノン
|
|
EP0234484B1
(en)
*
|
1986-02-19 |
1993-10-20 |
Sanraku Incorporated |
Novel azetidinone derivatives
|
|
GB8607312D0
(en)
*
|
1986-03-25 |
1986-04-30 |
Ici Plc |
Therapeutic agents
|
|
KR880701098A
(ko)
|
1986-04-01 |
1988-07-25 |
로버어트 에이 아미테이지 |
메틸프레드니솔론/소디움 카르복시메틸 전분 정제 조성물
|
|
FR2598146B1
(fr)
*
|
1986-04-30 |
1989-01-20 |
Rech Ind |
Nouveau procede de preparation de fibrates.
|
|
DE3621861A1
(de)
*
|
1986-06-30 |
1988-01-14 |
Laszlo Dr Med Ilg |
Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen
|
|
JPS6317859A
(ja)
|
1986-07-11 |
1988-01-25 |
Sagami Chem Res Center |
フルオロアゼチジノン誘導体
|
|
FR2602423B1
(fr)
*
|
1986-08-08 |
1989-05-05 |
Ethypharm Sa |
Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
|
|
US4814354A
(en)
*
|
1986-09-26 |
1989-03-21 |
Warner-Lambert Company |
Lipid regulating agents
|
|
CN87107149A
(zh)
|
1986-10-03 |
1988-05-18 |
伊莱利利公司 |
7-[(间位取代的)苯基甘氨酸]1-碳代-1-去硫头孢菌素
|
|
US4803266A
(en)
*
|
1986-10-17 |
1989-02-07 |
Taisho Pharmaceutical Co., Ltd. |
3-Oxoalkylidene-2-azetidinone derivatives
|
|
PH25145A
(en)
*
|
1986-12-15 |
1991-02-19 |
Laverne Dwaine Boeck |
Process for producing the a10255 complex and corresponding microorganism
|
|
US5229362A
(en)
*
|
1986-12-15 |
1993-07-20 |
Eli Lilly And Company |
Antibiotic A10255 complex and factors, and process and production therefor
|
|
ES2052584T3
(es)
|
1986-12-15 |
1994-07-16 |
Lilly Co Eli |
El complejo antibiotico a10255 y factores, proceso, microorganismos para su produccion.
|
|
JPS63156788A
(ja)
|
1986-12-22 |
1988-06-29 |
Sanraku Inc |
光学活性アゼチジノン類
|
|
WO1988005296A2
(en)
|
1987-01-27 |
1988-07-28 |
Warner-Lambert Company |
Lpid regulating compositions
|
|
US5110730A
(en)
*
|
1987-03-31 |
1992-05-05 |
The Scripps Research Institute |
Human tissue factor related DNA segments
|
|
US4879301A
(en)
*
|
1987-04-28 |
1989-11-07 |
Hoei Pharmaceutical Co., Ltd. |
Antiallergic and antiinflammatory benzothiazolinone derivatives
|
|
GB8710965D0
(en)
|
1987-05-08 |
1987-06-10 |
Smith Kline French Lab |
Pharmaceutical compositions
|
|
US5106833A
(en)
*
|
1987-07-23 |
1992-04-21 |
Washington University |
Coagulation inhibitors
|
|
YU46699B
(sh)
|
1987-10-06 |
1994-04-05 |
Eli Lilly And Co. |
Kristalni monohidratni oblik 1-karbacefalosporina
|
|
US5091525A
(en)
*
|
1987-10-07 |
1992-02-25 |
Eli Lilly And Company |
Monohydrate and DMF solvates of a new carbacephem antibiotic
|
|
US4834846A
(en)
*
|
1987-12-07 |
1989-05-30 |
Merck & Co., Inc. |
Process for deblocking N-substituted β-lactams
|
|
US5385885A
(en)
|
1988-01-15 |
1995-01-31 |
Gasic; Gregory P. |
Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide
|
|
FR2627696B1
(fr)
*
|
1988-02-26 |
1991-09-13 |
Fournier Innovation Synergie |
Nouvelle forme galenique du fenofibrate
|
|
DE3807895A1
(de)
*
|
1988-03-10 |
1989-09-21 |
Knoll Ag |
Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
|
|
EP0333268A1
(en)
|
1988-03-18 |
1989-09-20 |
Merck & Co. Inc. |
Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
|
|
IL89835A0
(en)
|
1988-04-11 |
1989-12-15 |
Merck & Co Inc |
Substituted azetidinones,their preparation and pharmaceutical compositions containing them
|
|
GB8813012D0
(en)
*
|
1988-06-02 |
1988-07-06 |
Norsk Hydro As |
Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
|
|
FR2634376B1
(fr)
|
1988-07-21 |
1992-04-17 |
Farmalyoc |
Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
|
|
US4952689A
(en)
*
|
1988-10-20 |
1990-08-28 |
Taisho Pharmaceutical Co., Ltd. |
3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
|
|
CA2002596A1
(en)
|
1988-11-14 |
1990-05-14 |
Thomas M. Eckrich |
Hydrates of b-lactam antibiotic
|
|
CA1340977C
(en)
|
1988-11-15 |
2000-04-25 |
Monty Krieger |
Scavenger receptor protein and antibody thereto
|
|
US5073374A
(en)
*
|
1988-11-30 |
1991-12-17 |
Schering Corporation |
Fast dissolving buccal tablet
|
|
US5112616A
(en)
*
|
1988-11-30 |
1992-05-12 |
Schering Corporation |
Fast dissolving buccal tablet
|
|
US4876365A
(en)
*
|
1988-12-05 |
1989-10-24 |
Schering Corporation |
Intermediate compounds for preparing penems and carbapenems
|
|
US5260305A
(en)
*
|
1988-12-12 |
1993-11-09 |
E. R. Squibb & Sons, Inc. |
Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
|
|
FR2640621B1
(fr)
|
1988-12-19 |
1992-10-30 |
Centre Nat Rech Scient |
N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
|
|
US4990535A
(en)
*
|
1989-05-03 |
1991-02-05 |
Schering Corporation |
Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
|
|
CA2016467A1
(en)
|
1989-06-05 |
1990-12-05 |
Martin Eisman |
Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
|
|
JPH03108490A
(ja)
*
|
1989-06-30 |
1991-05-08 |
Shionogi & Co Ltd |
フォスフォリパーゼａ↓２阻害物質
|
|
US5021461A
(en)
*
|
1989-07-26 |
1991-06-04 |
Merrell Dow Pharmaceuticals Inc. |
Method of treating diabetes mellitus with bisphenol derivatives
|
|
US4983597A
(en)
*
|
1989-08-31 |
1991-01-08 |
Merck & Co., Inc. |
Beta-lactams as anticholesterolemic agents
|
|
IL95574A
(en)
|
1989-09-09 |
1994-11-11 |
Knoll Ag |
Colestyramine preparation
|
|
US5219574A
(en)
*
|
1989-09-15 |
1993-06-15 |
Cima Labs. Inc. |
Magnesium carbonate and oil tableting aid and flavoring additive
|
|
US5223264A
(en)
*
|
1989-10-02 |
1993-06-29 |
Cima Labs, Inc. |
Pediatric effervescent dosage form
|
|
US5178878A
(en)
*
|
1989-10-02 |
1993-01-12 |
Cima Labs, Inc. |
Effervescent dosage form with microparticles
|
|
US5188825A
(en)
*
|
1989-12-28 |
1993-02-23 |
Iles Martin C |
Freeze-dried dosage forms and methods for preparing the same
|
|
CA2039763A1
(en)
|
1990-04-30 |
1991-10-31 |
Henry Y. Pan |
Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
|
|
CA2040865C
(en)
|
1990-05-15 |
2002-07-23 |
James L. Bergey |
Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
|
|
US5298497A
(en)
|
1990-05-15 |
1994-03-29 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of hypertension employing a cholesterol lowering drug
|
|
US5622985A
(en)
|
1990-06-11 |
1997-04-22 |
Bristol-Myers Squibb Company |
Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
|
|
CA2042526A1
(en)
|
1990-06-11 |
1991-12-12 |
Adeoye Y. Olukotun |
Method for preventing a second heart attack employing an hmg coa reductase inhibitor
|
|
US5120729A
(en)
*
|
1990-06-20 |
1992-06-09 |
Merck & Co., Inc. |
Beta-lactams as antihypercholesterolemics
|
|
ZA915372B
(en)
*
|
1990-07-17 |
1993-03-31 |
Lilly Co Eli |
Pyrazolidinone cck and gastrin antagonists and pharmaceutical formulations thereof
|
|
CA2048395A1
(en)
|
1990-08-23 |
1992-02-24 |
Henry Y. Pan |
Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
|
|
US5120713A
(en)
*
|
1990-09-10 |
1992-06-09 |
Applied Research Systems Ars Holding N.V. |
Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
|
|
US5075313A
(en)
|
1990-09-13 |
1991-12-24 |
Eli Lilly And Company |
3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
|
|
IL99658A0
(en)
|
1990-10-15 |
1992-08-18 |
Merck & Co Inc |
Substituted azetidinones and pharmaceutical compositions containing them
|
|
US5130333A
(en)
*
|
1990-10-19 |
1992-07-14 |
E. R. Squibb & Sons, Inc. |
Method for treating type II diabetes employing a cholesterol lowering drug
|
|
US5190970A
(en)
*
|
1990-10-19 |
1993-03-02 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
|
|
CA2052014A1
(en)
|
1990-10-19 |
1992-04-20 |
Henry Y. Pan |
Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
|
|
JP2640986B2
(ja)
*
|
1990-11-08 |
1997-08-13 |
高砂香料工業株式会社 |
（１′ｒ，３ｓ）―３―（１′―ヒドロキシエチル）―アゼチジン―２―オン又はその誘導体の製造法
|
|
IL100091A
(en)
|
1990-12-12 |
1998-08-16 |
Zeneca Ltd |
Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
|
|
US5145684A
(en)
*
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
|
US5552160A
(en)
|
1991-01-25 |
1996-09-03 |
Nanosystems L.L.C. |
Surface modified NSAID nanoparticles
|
|
US5399363A
(en)
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
|
AU642066B2
(en)
|
1991-01-25 |
1993-10-07 |
Nanosystems L.L.C. |
X-ray contrast compositions useful in medical imaging
|
|
IT1244699B
(it)
|
1991-02-01 |
1994-08-08 |
Luso Farmaco Inst |
Processo per la preparazione di acidi 3 acilammino-4- carbamoilossimetil-2-azetidinone-l-solfonici ed intermedi per la loro preparazione
|
|
US5157025A
(en)
*
|
1991-04-01 |
1992-10-20 |
E. R. Squibb & Sons, Inc. |
Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
|
|
US5348953A
(en)
|
1991-06-25 |
1994-09-20 |
Merck & Co., Inc. |
Substituted azetidinones as anti-inflammatory and antidegenerative agents
|
|
US5464632C1
(en)
|
1991-07-22 |
2001-02-20 |
Prographarm Lab |
Rapidly disintegratable multiparticular tablet
|
|
US5688785A
(en)
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
US5688787A
(en)
*
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
|
|
AU658441B2
(en)
|
1991-07-23 |
1995-04-13 |
Schering Corporation |
Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
|
|
US5561227A
(en)
|
1991-07-23 |
1996-10-01 |
Schering Corporation |
Process for the stereospecific synthesis of azetidinones
|
|
JP2620437B2
(ja)
|
1991-09-27 |
1997-06-11 |
宇部興産株式会社 |
ω−ヒドロキシ−（ω−３）−ケトニトリルおよびω−ヒドロキシ脂肪酸の製法
|
|
JPH06511250A
(ja)
|
1991-10-04 |
1994-12-15 |
ザ、プロクター、エンド、ギャンブル、カンパニー |
コレステロール低下化合物及びそれらの製造方法
|
|
US5162117A
(en)
*
|
1991-11-22 |
1992-11-10 |
Schering Corporation |
Controlled release flutamide composition
|
|
HUT67035A
(en)
|
1991-11-25 |
1995-01-30 |
Pfizer |
New process for the production of steroidal glycosides derivatives
|
|
DE4203932A1
(de)
|
1992-02-11 |
1993-08-12 |
Deutsche Aerospace |
Sende-/empfangsmodul
|
|
US6063764A
(en)
|
1992-06-01 |
2000-05-16 |
Washington University & Chiron Corp. |
Method for using lipoprotein associated coagulation inhibitor to treat sepsis
|
|
JPH07504921A
(ja)
|
1992-06-26 |
1995-06-01 |
フアイザー・インコーポレイテツド |
高コレステロール血症を治療するためのステロイドグリコシド
|
|
US5278176A
(en)
*
|
1992-08-21 |
1994-01-11 |
Abbott Laboratories |
Nicotine derivatives that enhance cognitive function
|
|
WO1994010143A1
(en)
|
1992-10-27 |
1994-05-11 |
Merck & Co., Inc. |
New substituted azetidinones as anti-inflammatory and antidegenerative agents
|
|
US5631363A
(en)
|
1992-11-13 |
1997-05-20 |
Tanabe Seiyaku Co., Ltd. |
Azetidinone compound and process for preparation thereof
|
|
NZ248813A
(en)
|
1992-11-25 |
1995-06-27 |
Eastman Kodak Co |
Polymeric grinding media used in grinding pharmaceutical substances
|
|
WO1994020535A1
(en)
|
1992-12-11 |
1994-09-15 |
Corvas International, Inc. |
ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
|
|
US5429824A
(en)
|
1992-12-15 |
1995-07-04 |
Eastman Kodak Company |
Use of tyloxapole as a nanoparticle stabilizer and dispersant
|
|
US5358852A
(en)
|
1992-12-21 |
1994-10-25 |
Eastman Kodak Company |
Use of calcium in immunoassay for measurement of C-reactive protein
|
|
LT3300B
(en)
|
1992-12-23 |
1995-06-26 |
Schering Corp |
Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
|
|
LT3595B
(en)
|
1993-01-21 |
1995-12-27 |
Schering Corp |
Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
|
|
US5563264A
(en)
|
1993-02-10 |
1996-10-08 |
Shionogi & Co., Ltd. |
Preparation of βlactam compounds
|
|
US5503846A
(en)
|
1993-03-17 |
1996-04-02 |
Cima Labs, Inc. |
Base coated acid particles and effervescent formulation incorporating same
|
|
US5412092A
(en)
|
1993-04-23 |
1995-05-02 |
Bristol-Myers Squibb Company |
N-substituted 2-azetidinones
|
|
IL109568A0
(en)
|
1993-05-19 |
1994-08-26 |
Fujisawa Pharmaceutical Co |
Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
|
|
US5703188A
(en)
|
1993-06-02 |
1997-12-30 |
Geltex Pharmaceuticals, Inc. |
Process for removing bile salts from a patient and compositions therefor
|
|
US5550229A
(en)
|
1993-06-23 |
1996-08-27 |
Tanabe Seiyaku Co., Ltd. |
Alkylation process for preparing azetidinone compound and starting compound therefor
|
|
DE69428280T2
(de)
|
1993-07-09 |
2002-06-13 |
Schering Corp., Kenilworth |
Verfahren zur herstellung von azetidinonen
|
|
ATE208615T1
(de)
|
1993-07-09 |
2001-11-15 |
Scherer Corp R P |
Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
|
|
WO1995004533A2
(en)
|
1993-08-04 |
1995-02-16 |
Andrulis Pharmaceuticals Corporation |
Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
|
|
AU7397094A
(en)
|
1993-08-30 |
1995-03-22 |
Merck & Co., Inc. |
Prevention and treatment of alzheimer's disease
|
|
US5851553A
(en)
|
1993-09-10 |
1998-12-22 |
Fuisz Technologies, Ltd. |
Process and apparatus for making rapidly dissolving dosage units and product therefrom
|
|
US5895664A
(en)
|
1993-09-10 |
1999-04-20 |
Fuisz Technologies Ltd. |
Process for forming quickly dispersing comestible unit and product therefrom
|
|
US5622719A
(en)
|
1993-09-10 |
1997-04-22 |
Fuisz Technologies Ltd. |
Process and apparatus for making rapidly dissolving dosage units and product therefrom
|
|
US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
US5976570A
(en)
|
1993-12-21 |
1999-11-02 |
Applied Analytical Industries, Inc. |
Method for preparing low dose pharmaceutical products
|
|
CA2180148A1
(en)
|
1993-12-28 |
1995-07-06 |
Michael Paul Deninno |
Hypocholesterolemic agents
|
|
US6369103B1
(en)
|
1994-01-18 |
2002-04-09 |
Bristol-Myers Squibb Company |
Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
|
|
US5595761A
(en)
|
1994-01-27 |
1997-01-21 |
The Board Of Regents Of The University Of Oklahoma |
Particulate support matrix for making a rapidly dissolving tablet
|
|
US5576014A
(en)
|
1994-01-31 |
1996-11-19 |
Yamanouchi Pharmaceutical Co., Ltd |
Intrabuccally dissolving compressed moldings and production process thereof
|
|
GB9401892D0
(en)
|
1994-02-01 |
1994-03-30 |
Boots Co Plc |
Therapeutic agents
|
|
US5635210A
(en)
|
1994-02-03 |
1997-06-03 |
The Board Of Regents Of The University Of Oklahoma |
Method of making a rapidly dissolving tablet
|
|
US5627176A
(en)
|
1994-03-25 |
1997-05-06 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
GB9406074D0
(en)
|
1994-03-26 |
1994-05-18 |
Glaxo Spa |
Chemical process
|
|
DE4414538A1
(de)
|
1994-04-26 |
1995-11-02 |
Klinge Co Chem Pharm Fab |
Präparate zur Therapie der kombinierten Hyperlipidämie mit einem Gehalt an einem p-Oxybenzoesäurederivat und einem Fibrat
|
|
US5554746A
(en)
|
1994-05-16 |
1996-09-10 |
Isis Pharmaceuticals, Inc. |
Lactam nucleic acids
|
|
US5718388A
(en)
|
1994-05-25 |
1998-02-17 |
Eastman Kodak |
Continuous method of grinding pharmaceutical substances
|
|
TW384224B
(en)
|
1994-05-25 |
2000-03-11 |
Nano Sys Llc |
Method of preparing submicron particles of a therapeutic or diagnostic agent
|
|
US5567439A
(en)
|
1994-06-14 |
1996-10-22 |
Fuisz Technologies Ltd. |
Delivery of controlled-release systems(s)
|
|
JPH10501811A
(ja)
*
|
1994-06-20 |
1998-02-17 |
シェーリング コーポレイション |
低コレステロール化剤として有用な置換アゼチジノン化合物
|
|
US6429289B1
(en)
|
1994-06-23 |
2002-08-06 |
Massachusetts Institute Of Technology |
Class BI and CI scavenger receptors
|
|
CA2200436A1
(en)
|
1994-09-20 |
1996-04-04 |
Pfizer Inc. |
Combination therapy for hypercholesterolemia
|
|
GB9421836D0
(en)
|
1994-10-28 |
1994-12-14 |
Scherer Corp R P |
Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
|
|
GB9421816D0
(en)
|
1994-10-29 |
1994-12-14 |
Smithkline Beecham Plc |
Novel compounds
|
|
US5633246A
(en)
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
US5624920A
(en)
|
1994-11-18 |
1997-04-29 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
US5656624A
(en)
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
|
FI972584L
(fi)
|
1994-12-22 |
1997-08-19 |
Smithkline Beecham Plc |
Substituoituja atsetidin-2-oneja ateroskleroosin hoitamiseksi
|
|
US5902726A
(en)
|
1994-12-23 |
1999-05-11 |
Glaxo Wellcome Inc. |
Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
|
|
PT801564E
(pt)
|
1994-12-28 |
2002-09-30 |
Janssen Pharmaceutica Nv |
Utilizacao de nebivolol como agente anti-aterogernico
|
|
US5545628A
(en)
|
1995-01-10 |
1996-08-13 |
Galephar P.R. Inc. |
Pharmaceutical composition containing fenofibrate
|
|
FR2730231B1
(fr)
|
1995-02-02 |
1997-04-04 |
Fournier Sca Lab |
Association de fenofibrate et de vitamine e, utilisation en therapeutique
|
|
US5639475A
(en)
|
1995-02-03 |
1997-06-17 |
Eurand America, Incorporated |
Effervescent microcapsules
|
|
US5518738A
(en)
|
1995-02-09 |
1996-05-21 |
Nanosystem L.L.C. |
Nanoparticulate nsaid compositions
|
|
US5591456A
(en)
|
1995-02-10 |
1997-01-07 |
Nanosystems L.L.C. |
Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
|
|
US5510118A
(en)
|
1995-02-14 |
1996-04-23 |
Nanosystems Llc |
Process for preparing therapeutic compositions containing nanoparticles
|
|
US5747001A
(en)
|
1995-02-24 |
1998-05-05 |
Nanosystems, L.L.C. |
Aerosols containing beclomethazone nanoparticle dispersions
|
|
US5998441A
(en)
|
1995-02-28 |
1999-12-07 |
Eli Lilly And Company |
Benzothiophene compounds, intermediates, compositions, and methods
|
|
US5639739A
(en)
|
1995-03-24 |
1997-06-17 |
The Dupont Merck Pharmaceutical Company |
Imidazole containing aminoboronic acids
|
|
US5759865A
(en)
|
1995-05-03 |
1998-06-02 |
Eli Lilly And Company |
Combinatorial process for synthesizing azetidinone analogs
|
|
DE19518988A1
(de)
|
1995-05-29 |
1996-12-05 |
Basf Ag |
Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
|
|
JP3144624B2
(ja)
*
|
1995-06-02 |
2001-03-12 |
杏林製薬株式会社 |
Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
|
|
US5612378A
(en)
|
1995-06-06 |
1997-03-18 |
3-Dimensional Pharmaceuticals, Inc. |
Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors
|
|
US5607697A
(en)
|
1995-06-07 |
1997-03-04 |
Cima Labs, Incorporated |
Taste masking microparticles for oral dosage forms
|
|
US5612353A
(en)
|
1995-06-07 |
1997-03-18 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
|
|
AU6039296A
(en)
|
1995-06-07 |
1996-12-30 |
G.D. Searle & Co. |
Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
|
|
NO318765B1
(no)
|
1995-07-03 |
2005-05-02 |
Sankyo Co |
Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
|
|
FR2737121B1
(fr)
|
1995-07-27 |
1997-10-03 |
Cl Pharma |
Nouvelles formulations galeniques du fenofibrate et leurs applications
|
|
US5698527A
(en)
|
1995-08-08 |
1997-12-16 |
Merck & Co., Inc. |
Steroidal glycosides as antihyperlipidemic agents
|
|
FR2738817B1
(fr)
|
1995-09-14 |
1997-10-17 |
Adir |
Nouveaux acides et esters 2,2-dimethyl-omega-phenoxy alcanoiques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US5618707A
(en)
|
1996-01-04 |
1997-04-08 |
Schering Corporation |
Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
|
|
CN1103780C
(zh)
|
1995-10-31 |
2003-03-26 |
先灵公司 |
用作降低血胆固醇药剂的糖取代2－氮杂环丁酮
|
|
US5808056A
(en)
|
1995-10-31 |
1998-09-15 |
Merck & Co., Inc. |
Process for preparing substituted azetidinones
|
|
WO1997016424A1
(en)
|
1995-11-02 |
1997-05-09 |
Schering Corporation |
Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
|
|
US5955105A
(en)
|
1995-11-14 |
1999-09-21 |
Knoll Pharmaceutical Company |
Stabilized thyroid hormone preparations and methods of making same
|
|
US5925333A
(en)
|
1995-11-15 |
1999-07-20 |
Massachusetts Institute Of Technology |
Methods for modulation of lipid uptake
|
|
JPH09143156A
(ja)
|
1995-11-17 |
1997-06-03 |
Tanabe Seiyaku Co Ltd |
アセトキシアゼチジノン誘導体の製法及びその合成中間体
|
|
US5807578A
(en)
|
1995-11-22 |
1998-09-15 |
Lab Pharmaceutical Research International Inc. |
Fast-melt tablet and method of making same
|
|
US5807577A
(en)
|
1995-11-22 |
1998-09-15 |
Lab Pharmaceutical Research International Inc. |
Fast-melt tablet and method of making same
|
|
JP2000505063A
(ja)
|
1995-12-08 |
2000-04-25 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
アテローム性動脈硬化症の治療のためのアゼチジノン化合物
|
|
US6080767A
(en)
|
1996-01-02 |
2000-06-27 |
Aventis Pharmaceuticals Products Inc. |
Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
|
|
GB9600464D0
(en)
|
1996-01-09 |
1996-03-13 |
Smithkline Beecham Plc |
Novel method
|
|
US5859051A
(en)
|
1996-02-02 |
1999-01-12 |
Merck & Co., Inc. |
Antidiabetic agents
|
|
US5847008A
(en)
|
1996-02-02 |
1998-12-08 |
Merck & Co., Inc. |
Method of treating diabetes and related disease states
|
|
WO1997028149A1
(en)
|
1996-02-02 |
1997-08-07 |
Merck & Co., Inc. |
Method for raising hdl cholesterol levels
|
|
GB9604242D0
(en)
|
1996-02-28 |
1996-05-01 |
Glaxo Wellcome Inc |
Chemical compounds
|
|
DE19608750A1
(de)
|
1996-03-06 |
1997-09-11 |
Durachemie Gmbh & Co Kg |
Verfahren zur Herstellung von Fenofibrat-Präparaten
|
|
IL117702A0
(en)
|
1996-03-28 |
1996-07-23 |
Tel Aviv Medical Center Resear |
Drug for hyperlipoproteinemia
|
|
GB9606805D0
(en)
|
1996-03-30 |
1996-06-05 |
Glaxo Wellcome Inc |
Medicaments
|
|
US5858409A
(en)
|
1996-04-17 |
1999-01-12 |
Fmc Corporation |
Hydrolyzed cellulose granulations for pharmaceuticals
|
|
CA2251972A1
(en)
*
|
1996-04-17 |
1997-10-23 |
Merck & Co., Inc. |
Combination therapy for reducing the risks associated with cardiovascular disease
|
|
CA2252696A1
(en)
|
1996-04-26 |
1997-11-06 |
Deirdre Mary Bernadette Hickey |
Azetidinone derivatives for the treatment of atherosclerosis
|
|
US5843984A
(en)
|
1996-05-09 |
1998-12-01 |
Eli Lilly And Company |
Sulfated benzothiophene derivatives, methods of use and formulations containing same
|
|
CA2255663C
(en)
*
|
1996-05-24 |
2002-08-20 |
Schering Corporation |
Antifungal composition with enhanced bioavailability
|
|
US5886171A
(en)
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
|
US5739321A
(en)
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
|
US6245743B1
(en)
|
1996-06-05 |
2001-06-12 |
Cor Therapeutics, Inc. |
Inhibitors of factor Xa
|
|
GB9611947D0
(en)
|
1996-06-07 |
1996-08-07 |
Glaxo Group Ltd |
Medicaments
|
|
US5998421A
(en)
|
1996-06-12 |
1999-12-07 |
Kyowa Hakko Kogyo Co., Ltd. |
Lipid metabolism ameliorants
|
|
US5965553A
(en)
|
1996-06-20 |
1999-10-12 |
Pfizer Inc. |
Squalene synthetase inhibitors
|
|
AU4228997A
(en)
|
1996-07-09 |
1998-02-02 |
Merck & Co., Inc. |
Method for treating homozygous familial hypercholesterolemia
|
|
US6139873A
(en)
|
1996-07-10 |
2000-10-31 |
Cedars-Sinai Medical Center |
Combined pharmaceutical estrogen-androgen-progestin
|
|
US5883109A
(en)
|
1996-07-24 |
1999-03-16 |
Bristol-Myers Squibb Company |
Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
|
|
US5952003A
(en)
|
1996-08-01 |
1999-09-14 |
Novartis Corporation |
Terazosin capsules
|
|
EP0930882A2
(en)
|
1996-08-02 |
1999-07-28 |
Institut Pasteur De Lille |
Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
|
|
US6057342A
(en)
|
1996-08-16 |
2000-05-02 |
Dupont Pharmaceutical Co. |
Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
|
|
US6235706B1
(en)
|
1996-09-18 |
2001-05-22 |
Merck & Co., Inc. |
Combination therapy for reducing the risks associated with cardiovascular disease
|
|
US6251852B1
(en)
|
1996-09-18 |
2001-06-26 |
Merck & Co., Inc. |
Combination therapy for reducing the risks associated with cardiovascular disease
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
US5959123A
(en)
|
1996-09-23 |
1999-09-28 |
Synphar Laboratories, Inc. |
3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators
|
|
KR100353304B1
(ko)
|
1996-10-01 |
2002-09-30 |
에스알아이 인터내셔널 |
맛이 차폐된 마이크로캡슐 조성물 및 이것의 제조 방법
|
|
US6262047B1
(en)
|
1996-10-11 |
2001-07-17 |
Cor Therapeutics, Inc. |
Selective factor Xa inhibitors
|
|
US5756470A
(en)
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
ES2230624T5
(es)
|
1996-11-27 |
2010-10-25 |
Aventis Pharmaceuticals Inc. |
Composicion farmaceutica que comprende un compuesto que tiene actividad anti-xa y un compuesto antagonista de la agregacion plaquetaria.
|
|
US6090839A
(en)
|
1996-12-23 |
2000-07-18 |
Merck & Co., Inc. |
Antidiabetic agents
|
|
FR2758459B1
(fr)
|
1997-01-17 |
1999-05-07 |
Pharma Pass |
Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
|
|
EP0989852A4
(en)
|
1997-01-17 |
2002-11-13 |
Bristol Myers Squibb Co |
METHODS FOR TREATING ATHEROSCLEROSE THROUGH AN MPT INHIBITOR AND CHOLESTEROL LEVELS LOWERING MEDICINES
|
|
US6066653A
(en)
|
1997-01-17 |
2000-05-23 |
Bristol-Myers Squibb Co. |
Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
|
|
FR2758461A1
(fr)
|
1997-01-17 |
1998-07-24 |
Pharma Pass |
Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
|
|
EP2251036A1
(en)
*
|
1997-02-28 |
2010-11-17 |
Sanofi Pasteur Biologics Co. |
Chimeric flavivirus vaccines
|
|
AU6773598A
(en)
|
1997-03-26 |
1998-10-20 |
Institut Pasteur |
Treatment of gastrointestinal disease with ppar modulators
|
|
FR2761266B1
(fr)
*
|
1997-03-28 |
1999-07-02 |
Sanofi Sa |
Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
|
|
CA2285091A1
(en)
|
1997-04-02 |
1998-10-08 |
Brigham And Women's Hospital, Inc. |
Means of ascertaining an individual's risk profile for atherosclerotic disease
|
|
US6024981A
(en)
|
1997-04-16 |
2000-02-15 |
Cima Labs Inc. |
Rapidly dissolving robust dosage form
|
|
DE19716120A1
(de)
|
1997-04-17 |
1998-10-22 |
Europ Lab Molekularbiolog |
Verwendung von cholesterinsenkenden Mitteln
|
|
AU735760B2
(en)
|
1997-04-24 |
2001-07-12 |
Merck Sharp & Dohme Limited |
Use of a NK-1 receptor antagonist and an SSRI for treating obesity
|
|
ES2125198B1
(es)
*
|
1997-05-13 |
1999-11-16 |
Vita Invest Sa |
Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
|
|
DE69829966T2
(de)
|
1997-05-14 |
2006-02-09 |
Atherogenics, Inc. |
Ein monoether von probucol und methoden zur hemmung der vcam-1 expression
|
|
US6423754B1
(en)
|
1997-06-18 |
2002-07-23 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with polyallylamine polymers
|
|
US6300364B1
(en)
|
1997-07-24 |
2001-10-09 |
Yamanouchi Pharmaceutical Co., Ltd. |
Medicinal compositions with cholesterol-lowering effect
|
|
DE69837610T2
(de)
|
1997-07-31 |
2008-01-03 |
Kos Life Sciences, Inc., Weston |
Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird in verzögert freigesetzter form und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung
|
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
|
US6117429A
(en)
|
1997-08-11 |
2000-09-12 |
Weider Nutrition International, Inc |
Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
|
|
US5886191A
(en)
|
1997-08-18 |
1999-03-23 |
Dupont Pharmaceuticals Company |
Amidinoindoles, amidinoazoles, and analogs thereof
|
|
US5869098A
(en)
|
1997-08-20 |
1999-02-09 |
Fuisz Technologies Ltd. |
Fast-dissolving comestible units formed under high-speed/high-pressure conditions
|
|
AR016827A1
(es)
*
|
1997-08-22 |
2001-08-01 |
Smithkline Beecham Corp |
PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
|
|
CA2300165A1
(en)
|
1997-08-26 |
1999-03-04 |
Merck & Co., Inc. |
Cholesterol-lowering therapy
|
|
WO2001018210A1
(en)
|
1999-09-08 |
2001-03-15 |
Genentech, Inc. |
Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
|
|
US6180660B1
(en)
|
1997-08-26 |
2001-01-30 |
Merck & Co., Inc. |
Cholesterol-lowering therapy
|
|
US6143885A
(en)
|
1997-08-27 |
2000-11-07 |
Merck & Co., Inc. |
Preparation of beta-methyl carbapenem intermediates
|
|
GT199800126A
(es)
|
1997-08-29 |
2000-01-29 |
|
Terapia de combinacion.
|
|
JP2001515887A
(ja)
|
1997-09-09 |
2001-09-25 |
デュポン ファーマシューティカルズ カンパニー |
Ｘａ因子の阻害剤としての、ベンゾイミダゾリノン類、ベンゾオキサゾリノン類、ベンゾピペラジノン類、インダノン類、およびそれらの誘導体
|
|
AU8996698A
(en)
|
1997-09-10 |
1999-03-29 |
Ono Pharmaceutical Co. Ltd. |
Peroxisome proliferator-activated receptor controllers
|
|
GB2329334A
(en)
|
1997-09-18 |
1999-03-24 |
Reckitt & Colmann Prod Ltd |
Cholesterol-lowering agents
|
|
CA2214895C
(en)
|
1997-09-19 |
1999-04-20 |
Bernard Charles Sherman |
Improved pharmaceutical composition comprising fenofibrate
|
|
AU9002798A
(en)
|
1997-09-19 |
1999-04-12 |
Ono Pharmaceutical Co. Ltd. |
Fused or nonfused benzene compounds
|
|
CA2304505A1
(en)
|
1997-09-24 |
1999-04-01 |
Nova Molecular, Inc. |
Methods for increasing apoe levels for the treatment of neurodegenerative disease
|
|
IE970731A1
(en)
|
1997-10-07 |
2000-10-04 |
Fuisz Internat Ltd |
Product and method for the treatment of hyperlipidemia
|
|
US6242439B1
(en)
|
1997-10-07 |
2001-06-05 |
Boehringer Ingelheim (Canada) Ltd. |
Azetidinone derivatives for the treatment of HCMV infections
|
|
US6147109A
(en)
|
1997-10-14 |
2000-11-14 |
The General Hospital Corporation |
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
|
US6005102A
(en)
|
1997-10-15 |
1999-12-21 |
American Home Products Corporation |
Aryloxy-alkyl-dialkylamines
|
|
EP1030665A4
(en)
|
1997-10-17 |
2002-11-27 |
Aventis Pharm Prod Inc |
THERAPEUTIC USE OF CHINOLINE DERIVATIVES
|
|
US20030153541A1
(en)
*
|
1997-10-31 |
2003-08-14 |
Robert Dudley |
Novel anticholesterol compositions and method for using same
|
|
WO1999022728A1
(en)
|
1997-10-31 |
1999-05-14 |
Arch Development Corporation |
Methods and compositions for regulation of 5-alpha reductase activity
|
|
US6027747A
(en)
|
1997-11-11 |
2000-02-22 |
Terracol; Didier |
Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
|
|
AU1809499A
(en)
|
1997-12-10 |
1999-06-28 |
Awadhesh K. Mishra |
Self-emulsifying fenofibrate formulations
|
|
US5985936A
(en)
|
1997-12-18 |
1999-11-16 |
Forbes Medi-Tech, Inc. |
Method of preventing and delaying onset of Alzheimer's disease and composition therefor
|
|
US6008237A
(en)
|
1997-12-19 |
1999-12-28 |
Merck & Co., Inc. |
Arylthiazolidinedione derivatives
|
|
NZ505761A
(en)
|
1998-01-28 |
2003-08-29 |
Warner Lambert Co |
Method for treating alzheimer's disease using plasma-triglceride level-lowering agents or agents that interfer with cholesterol ester synthesis
|
|
US6200995B1
(en)
|
1998-01-29 |
2001-03-13 |
Tularik Inc. |
PPAR-γ modulators
|
|
AU1887999A
(en)
|
1998-01-29 |
1999-08-16 |
Dr. Reddy's Research Foundation |
Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
|
|
US6133001A
(en)
|
1998-02-23 |
2000-10-17 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
|
|
KR100620337B1
(ko)
|
1998-03-10 |
2006-09-13 |
오노 야꾸힝 고교 가부시키가이샤 |
카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
|
|
US6235311B1
(en)
|
1998-03-18 |
2001-05-22 |
Bristol-Myers Squibb Company |
Pharmaceutical composition containing a combination of a statin and aspirin and method
|
|
US6080778A
(en)
|
1998-03-23 |
2000-06-27 |
Children's Medical Center Corporation |
Methods for decreasing beta amyloid protein
|
|
US6180625B1
(en)
|
1998-03-24 |
2001-01-30 |
Novo Nordisk A/S |
Heterocyclic compounds regulating clotting
|
|
DE69920888T2
(de)
|
1998-03-27 |
2006-02-02 |
Bristol-Myers Squibb Pharma Co. |
Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
|
|
WO1999008501A2
(en)
*
|
1998-04-23 |
1999-02-25 |
Dr. Reddy's Research Foundation |
New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
|
|
CN1289475C
(zh)
|
1998-04-29 |
2006-12-13 |
奥索-麦克尼尔药品公司 |
在肥胖症和其它病症的治疗中用作神经肽yy5受体配体的n－取代的氨基1,2,3,4－四氢化萘
|
|
NZ504106A
(en)
|
1998-05-27 |
2003-02-28 |
Dr |
Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
|
|
US6262042B1
(en)
|
1998-05-29 |
2001-07-17 |
Research Triangle Institute |
17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
|
|
FR2779347A1
(fr)
|
1998-06-05 |
1999-12-03 |
Arlette Guerry |
Procede de micronisation de substances medicamenteuses
|
|
EP1089731A4
(en)
|
1998-06-24 |
2003-06-18 |
Merck & Co Inc |
COMPOSITIONS AND METHOD FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
|
|
EP1089732A4
(en)
|
1998-06-24 |
2001-09-19 |
Merck & Co Inc |
COMPOSITIONS AND METHODS FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
|
|
US6099865A
(en)
|
1998-07-08 |
2000-08-08 |
Fmc Corporation |
Croscarmellose taste masking
|
|
FR2781222A1
(fr)
|
1998-07-17 |
2000-01-21 |
Lipha |
Composes cycliques utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procede de preparation
|
|
DE69911975T2
(de)
|
1998-07-31 |
2004-09-09 |
Novo Nordisk A/S |
In-vitro stimulation von beta zellen vermehrung
|
|
DE69929345T2
(de)
|
1998-08-07 |
2006-09-21 |
Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville |
Substituierte isoxal-derivate als östrogenrezeptormodulatoren
|
|
US6147090A
(en)
|
1998-09-17 |
2000-11-14 |
Pfizer Inc. |
4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
|
|
FR2783421B1
(fr)
|
1998-09-17 |
2000-11-24 |
Cll Pharma |
Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
|
|
BR9914098A
(pt)
|
1998-09-30 |
2001-07-31 |
Warner Lambert Co |
Método para impedir ou retardar revascularização à base de cateter
|
|
US5919672A
(en)
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
|
EP1123292A1
(en)
|
1998-10-21 |
2001-08-16 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
EP1123268A1
(en)
|
1998-10-21 |
2001-08-16 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
EP1123267A1
(en)
|
1998-10-21 |
2001-08-16 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
WO2000023425A1
(en)
|
1998-10-21 |
2000-04-27 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
US6248781B1
(en)
|
1998-10-21 |
2001-06-19 |
Novo Nordisk A/S |
Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
|
|
JP2002527520A
(ja)
|
1998-10-21 |
2002-08-27 |
ノボ ノルディスク アクティーゼルスカブ |
新規化合物、その製造及び使用
|
|
CA2253769C
(en)
|
1998-11-10 |
2000-09-26 |
Bernard Charles Sherman |
Pharmaceutical compositions comprising fenofibrate
|
|
US6472421B1
(en)
|
1998-11-13 |
2002-10-29 |
Nymox Corporation |
Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
|
|
WO2000031548A1
(en)
|
1998-11-25 |
2000-06-02 |
Scios Inc. |
Prevention and treatment of amyloid-associated disorders
|
|
SA99191255B1
(ar)
|
1998-11-30 |
2006-11-25 |
جي دي سيرل اند كو |
مركبات سيليكوكسيب celecoxib
|
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
|
JP3640888B2
(ja)
|
1998-12-07 |
2005-04-20 |
シェーリング コーポレイション |
アゼチジノンの合成プロセス
|
|
US6277584B1
(en)
|
1998-12-16 |
2001-08-21 |
Dade Behring Inc. |
Method for calibrating a chemical analyzer with improved accuracy at low signal levels
|
|
EP1140036A2
(en)
|
1998-12-18 |
2001-10-10 |
Abbott Laboratories |
Novel formulations comprising lipid-regulating agents
|
|
DE19858789A1
(de)
|
1998-12-18 |
2000-06-21 |
Bayer Ag |
Kombination von Cerivastatin und Fibraten
|
|
DK1140191T3
(da)
|
1998-12-23 |
2003-02-24 |
Searle Llc |
Kombinationer af ileumgaldesyretransportinhibitorer og nicotinsyrederivater til cardiovaskulære indikationer
|
|
WO2000038724A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
|
AU779264B2
(en)
*
|
1998-12-23 |
2005-01-13 |
G.D. Searle Llc |
Combinations for cardiovascular indications
|
|
ATE242007T1
(de)
|
1998-12-23 |
2003-06-15 |
Searle Llc |
Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
|
|
WO2000038728A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
|
|
WO2000038722A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle & Co. |
COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
|
|
EA005815B1
(ru)
|
1998-12-23 |
2005-06-30 |
Джи.Ди.Сирл Ллс |
Комбинация ингибиторов транспорта желчных кислот в подвздошной кишке и ингибиторов белка, переносящего эфиры холестерина, для сердечно-сосудистых показаний
|
|
ATE242008T1
(de)
|
1998-12-23 |
2003-06-15 |
Searle Llc |
Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
|
|
ATE240120T1
(de)
|
1998-12-23 |
2003-05-15 |
Searle Llc |
Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
|
|
AR022204A1
(es)
|
1999-01-08 |
2002-09-04 |
Norgine Bv |
Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
|
|
US6180138B1
(en)
|
1999-01-29 |
2001-01-30 |
Abbott Laboratories |
Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
|
|
GB0000710D0
(en)
|
1999-02-06 |
2000-03-08 |
Zeneca Ltd |
Drug combination
|
|
WO2000050392A1
(en)
|
1999-02-24 |
2000-08-31 |
Sankyo Company, Limited |
2-mercaptocarboxylic acid derivatives
|
|
AU2866400A
(en)
|
1999-03-08 |
2000-09-28 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
|
|
EP1036563A1
(en)
|
1999-03-08 |
2000-09-20 |
MERCK & CO. INC. |
Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
|
|
EP1637137A3
(en)
|
1999-03-10 |
2006-07-05 |
G.D. Searle LLC |
Method and composition for administering a cyclooxygenase-2 inhibitor to animals
|
|
TR200202077T2
(tr)
|
1999-03-11 |
2002-11-21 |
Nuclear Receptor Research Limited |
Prar nükleer reseptörleri için yeni ligandlar
|
|
EP1175246A4
(en)
|
1999-03-19 |
2004-12-15 |
Brigham & Womens Hospital |
POSITIVE REGULATION OF NITRIC OXIDE SYNTHASE OF TYPE III ENDOTHELIAL CELLS BY HMG-COA REDUCTASE INHIBITORS
|
|
WO2000057918A2
(en)
|
1999-03-31 |
2000-10-05 |
Abbott Laboratories |
Novel formulations comprising lipid-regulating agents
|
|
JP2003520767A
(ja)
|
1999-03-31 |
2003-07-08 |
アボット・ラボラトリーズ |
脂質調整剤を含む新規製剤
|
|
JP3679715B2
(ja)
|
1999-04-05 |
2005-08-03 |
シェーリング コーポレイション |
１−（４−フルオロフェニル）−３（ｒ）−［３（ｓ）−ヒドロキシ−３−（４−フルオロフェニル）プロピル）］−４（ｓ）−（４−ヒドロキシフェニル）−２−アゼチジノンの調製のための立体選択的微生物還元
|
|
US6593078B1
(en)
|
1999-04-16 |
2003-07-15 |
Schering Corporation |
Use of azetidinone compounds
|
|
JP2002542224A
(ja)
|
1999-04-19 |
2002-12-10 |
コーエラカント コーポレイション |
Ｉｉ型糖尿病の治療薬としてのｐｐａｒ−（ガンマ）作用物質
|
|
AU3958100A
(en)
|
1999-04-20 |
2000-11-02 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
BR0009864A
(pt)
|
1999-04-20 |
2002-01-08 |
Novo Nordisk As |
Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto
|
|
JP2002542237A
(ja)
|
1999-04-20 |
2002-12-10 |
ノボ ノルディスク アクティーゼルスカブ |
新規な化合物、それらの製造及び使用
|
|
WO2000063196A1
(en)
|
1999-04-20 |
2000-10-26 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
CA2270306C
(en)
|
1999-04-27 |
2000-09-26 |
Bernard Charles Sherman |
Pharmaceutical compositions comprising co-micronized fenofibrate
|
|
US6033656A
(en)
|
1999-05-04 |
2000-03-07 |
Sumitomo Chemical Company, Limited |
Method of preventing or alleviating mammalian obesity
|
|
WO2000069445A1
(en)
|
1999-05-13 |
2000-11-23 |
Geltex Pharmaceuticals, Inc. |
Combination therapy for treating hypercholesterolemia
|
|
HK1044897A1
(zh)
|
1999-05-14 |
2002-11-08 |
Esperion Luv Development Inc. |
心绞痛和/或不典型心绞痛的治疗方法及其相关药物组合物和药剂盒
|
|
JP2003500439A
(ja)
|
1999-05-28 |
2003-01-07 |
アボット・ラボラトリーズ |
脂質調節剤を含む新規調合物
|
|
US6465011B2
(en)
|
1999-05-29 |
2002-10-15 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
|
JP4618845B2
(ja)
|
1999-06-09 |
2011-01-26 |
杏林製薬株式会社 |
ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
|
|
US6372251B2
(en)
|
1999-06-11 |
2002-04-16 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
|
GB9913782D0
(en)
|
1999-06-14 |
1999-08-11 |
Smithkline Beecham Plc |
Novel compounds
|
|
US6380191B1
(en)
|
1999-06-18 |
2002-04-30 |
Merck & Co. Inc. |
Arylthiazolidinedione and aryloxazolidinedione derivatives
|
|
CA2376919C
(en)
|
1999-06-18 |
2008-11-04 |
Merck & Co., Inc. |
Arylthiazolidinedione and aryloxazolidinedione derivatives
|
|
US6207699B1
(en)
|
1999-06-18 |
2001-03-27 |
Richard Brian Rothman |
Pharmaceutical combinations for treating obesity and food craving
|
|
GB9914977D0
(en)
|
1999-06-25 |
1999-08-25 |
Glaxo Group Ltd |
Chemical compounds
|
|
JP4295458B2
(ja)
|
1999-06-30 |
2009-07-15 |
アムジェン インコーポレイテッド |
Ｐｐａｒ−ガンマ活性調節用化合物
|
|
AU4491200A
(en)
|
1999-08-03 |
2001-02-19 |
Lilly Icos Llc |
Beta-carboline pharmaceutical compositions
|
|
EP1078632A1
(en)
|
1999-08-16 |
2001-02-28 |
Sanofi-Synthelabo |
Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
|
|
GB9919411D0
(en)
|
1999-08-18 |
1999-10-20 |
Zeneca Ltd |
Chemical compounds
|
|
GB9919413D0
(en)
|
1999-08-18 |
1999-10-20 |
Zeneca Ltd |
Chemical compounds
|
|
AU778720B2
(en)
|
1999-08-23 |
2004-12-16 |
Kyorin Pharmaceutical Co. Ltd. |
Substituted benzylthiazolidine-2,4-dione derivatives
|
|
AU778723B2
(en)
|
1999-08-23 |
2004-12-16 |
Kyorin Pharmaceutical Co. Ltd. |
Substituted benzylthiazolidine-2,4-dione derivatives
|
|
CA2382573C
(en)
|
1999-08-23 |
2007-05-22 |
Kyorin Pharmaceutical Co., Ltd. |
Substituted benzylthiazolidine-2,4-dione derivatives
|
|
AU7073400A
(en)
|
1999-08-27 |
2001-03-26 |
Eli Lilly And Company |
Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
|
|
CA2381926A1
(en)
|
1999-08-31 |
2001-03-08 |
Brigham And Women's Hospital, Inc. |
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
|
|
ES2215719T3
(es)
|
1999-09-08 |
2004-10-16 |
Glaxo Group Limited |
Antagonista ppar oxazol.
|
|
US6174665B1
(en)
|
1999-09-10 |
2001-01-16 |
Biex, Inc. |
Hormone replacement therapy monitoring
|
|
ATE316071T1
(de)
|
1999-09-17 |
2006-02-15 |
Kyorin Seiyaku Kk |
O-anisamid-derivate
|
|
EP1225901A2
(en)
|
1999-09-21 |
2002-07-31 |
Emory University |
Uses and compositions for treating platelet-related disorders using anagrelide
|
|
EP1214351A2
(en)
|
1999-09-22 |
2002-06-19 |
Genset |
Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
|
|
DE69923718T2
(de)
|
1999-09-24 |
2006-01-12 |
Kyorin Pharmaceutical Co., Ltd. |
Ppar-alpha und ppar-gamma-hemmer
|
|
AU7717500A
(en)
|
1999-09-30 |
2001-04-30 |
Merck & Co., Inc. |
Anti-hypercholesterolemic drug combination
|
|
AU2833701A
(en)
|
1999-09-30 |
2001-05-10 |
Shell Internationale Research Maatschappij B.V. |
Adducts of glycidylesters of alpha, alpha-branched carboxylic acids and carboxylic acids and poly(ortho ester) as intermediate for their preparation
|
|
AU7995300A
(en)
|
1999-10-05 |
2001-05-10 |
Bethesda Pharmaceuticals, Inc. |
Dithiolane derivatives
|
|
WO2001030343A1
(en)
|
1999-10-22 |
2001-05-03 |
Merck & Co., Inc. |
Pharmaceuticals for treating obesity
|
|
NZ518822A
(en)
|
1999-11-04 |
2004-12-24 |
Andrx Corp |
Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
|
|
CA2390557A1
(en)
|
1999-11-11 |
2001-05-17 |
Kyorin Pharmaceutical Co., Ltd. |
Solid preparations for oral use
|
|
JP2003514024A
(ja)
|
1999-11-12 |
2003-04-15 |
オンコリティクス バイオテク，インコーポレーテッド |
細胞増殖性疾患の治療のためのウイルス
|
|
WO2001040192A1
(en)
|
1999-12-03 |
2001-06-07 |
Kyoto Pharmaceutical Industries, Ltd. |
Novel heterocyclic compounds and salts thereof and medicinal use of the same
|
|
DE60019741T2
(de)
|
1999-12-08 |
2006-03-02 |
Pharmacia Corp., Chicago |
Nanopartikelzusammensetzungen enthaltend eplerenon
|
|
AU2276801A
(en)
|
1999-12-20 |
2001-07-03 |
Schering Corporation |
Extended release oral dosage composition
|
|
US6248359B1
(en)
|
2000-01-05 |
2001-06-19 |
Laboratorios Phoenix U.S.A., Inc. |
Multi-tablet oxybutynin system for treating incontinence
|
|
WO2001056579A1
(en)
|
2000-02-04 |
2001-08-09 |
Esperion Therapeutics Inc. |
Methods for treating alzheimer's disease
|
|
CA2400021A1
(en)
|
2000-02-18 |
2001-08-23 |
Merck & Co., Inc. |
Aryloxyacetic acids for diabetes and lipid disorders
|
|
ATE312613T1
(de)
|
2000-02-29 |
2005-12-15 |
Bristol Myers Squibb Co |
Niedrig dosierte entecavir formulierung und deren verwendung
|
|
CA2406077C
(en)
|
2000-04-10 |
2010-07-20 |
Nicholas J. Wald |
Formulation for the prevention of cardiovascular disease
|
|
US6316029B1
(en)
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
|
US20020013334A1
(en)
|
2000-06-15 |
2002-01-31 |
Robl Jeffrey A. |
HMG-CoA reductase inhibitors and method
|
|
US6191117B1
(en)
|
2000-07-10 |
2001-02-20 |
Walter E. Kozachuk |
Methods of producing weight loss and treatment of obesity
|
|
AU7705601A
(en)
|
2000-07-25 |
2002-02-05 |
Merck & Co Inc |
N-substituted indoles useful in the treatment of diabetes
|
|
US20020132855A1
(en)
*
|
2000-08-03 |
2002-09-19 |
Nelson Edward B. |
Use of acetaminophen to prevent and treat arteriosclerosis
|
|
DE10042447A1
(de)
*
|
2000-08-29 |
2002-03-28 |
Aventis Pharma Gmbh |
Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
|
|
AU2001292874B2
(en)
*
|
2000-09-27 |
2006-06-15 |
Merck & Co., Inc. |
Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
|
|
AU2002231049B2
(en)
|
2000-12-20 |
2006-07-20 |
Merck Sharp & Dohme Corp. |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
US6982251B2
(en)
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
CN1217927C
(zh)
*
|
2000-12-21 |
2005-09-07 |
阿文蒂斯药物德国有限公司 |
新的1,2－二苯基氮杂环丁烷酮、其制备方法、含有所述化合物的药物及其在治疗脂质代谢病症中的应用
|
|
HRP20030501A2
(en)
*
|
2000-12-21 |
2005-04-30 |
Aventis Pharma Deutschland Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
|
IL156552A0
(en)
*
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
|
AU2002247019C1
(en)
|
2001-01-26 |
2017-05-11 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
ATE369851T1
(de)
|
2001-01-26 |
2007-09-15 |
Schering Corp |
Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
|
|
CN1582168A
(zh)
|
2001-01-26 |
2005-02-16 |
先灵公司 |
用于治疗血管性疾病的固醇吸收抑制剂与心血管药剂的组合
|
|
ES2296894T3
(es)
|
2001-01-26 |
2008-05-01 |
Schering Corporation |
Combinaciones de ezetimiba con aspirina para tratar estados vasculares.
|
|
AR034204A1
(es)
|
2001-01-26 |
2004-02-04 |
Schering Corp |
Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares
|
|
RU2756946C2
(ru)
|
2001-01-26 |
2021-10-07 |
Мерк Шарп И Доум Корп. |
Применение замещенных азетидинонов для лечения ситостеролемии
|
|
CA2437118A1
(en)
*
|
2001-02-09 |
2002-08-22 |
Merck & Co., Inc. |
2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
|
|
DE10106787A1
(de)
|
2001-02-12 |
2002-08-22 |
Nanogate Gmbh |
Wasserfrei hydrolisierte Sol-Gel-Systeme
|
|
EP1372632A1
(en)
|
2001-02-15 |
2004-01-02 |
Pfizer Products Inc. |
Proliferative activator receptor (ppar) compounds
|
|
EP1360172A1
(en)
|
2001-02-15 |
2003-11-12 |
Pfizer Products Inc. |
Ppar agonists
|
|
EP1389114A2
(en)
*
|
2001-03-08 |
2004-02-18 |
Merck & Co., Inc. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
|
WO2002081454A1
(en)
*
|
2001-04-09 |
2002-10-17 |
Dr. Reddy's Laboratories Ltd. |
Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
|
|
US7348334B2
(en)
*
|
2001-04-09 |
2008-03-25 |
Dr. Reddy's Laboratories Limited |
Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them
|
|
EP1392287B8
(en)
|
2001-05-25 |
2007-01-10 |
Schering Corporation |
Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
|
|
EP1420826A2
(de)
|
2001-08-22 |
2004-05-26 |
Aventis Pharma Deutschland GmbH |
Kombinationspräparate von arylsubstituierten propanolaminderivaten mit weiteren wirkstoffen und deren verwendung
|
|
EP1425018B1
(de)
|
2001-08-22 |
2008-10-22 |
Sanofi-Aventis Deutschland GmbH |
Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung
|
|
DE60229406D1
(de)
|
2001-09-21 |
2008-11-27 |
Schering Corp |
Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
|
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
DE60216300T2
(de)
|
2001-09-21 |
2007-06-28 |
Schering Corp. |
Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
|
|
US20030119808A1
(en)
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
|
WO2003039542A1
(en)
|
2001-10-17 |
2003-05-15 |
Merck & Co. Inc. |
Combination therapy for treating alzheimer's disease
|
|
US20050123580A1
(en)
|
2002-02-28 |
2005-06-09 |
Burris Thomas P. |
Method of treating atherosclerosis and hypercholesterolemia
|
|
AU2003225027A1
(en)
|
2002-04-16 |
2003-11-03 |
Merck And Co., Inc. |
Combination therapy using a ppar alpha/gamma agonist
|